Department of Hematology, The Affiliated Hospital of Chengde Medical College , Chengde, Hebei, China.
Cell Cycle. 2020 Aug;19(16):2063-2073. doi: 10.1080/15384101.2020.1792686. Epub 2020 Jul 17.
PURPOSE: This study aimed to explore the effect of GANT61 on regulating cell proliferation, cell apoptosis and cell cycle, and to investigate whether GANT61 would function in multiple myeloma (MM) via inhibiting Notch pathway. : RPMI-8226 and U266 cells were treated by GANT61 (0, 2.5, 5.0, 10.0, 20.0, 30.0, 40.0, 50.0 μmol/L) for 18, 24 and 36 hours (h), and cell proliferation was detected by Cell Counting Kit 8. Then these cells were treated by GANT61 at 0, 2.5, 5.0, 10.0 μmol/L for 24 h or treated by 10.0 μmol/L GANT61 for 0, 18, 24 and 36 h, and cell apoptosis rate, apoptosis markers and cell cycle were detected by AV/PI, Western blot, and PI staining. Notch1, Jagged1, Jagged2 and Hes1 expressions were detected by qPCR and Western blot. Further rescue experiments were conducted by upregulating Notch1. : In RPMI-8226 and U266 cells, GANT61 inhibited cell proliferation, increased cell apoptosis rate and cell percentage of G1/G0 phase while decreased cell percentage of S phase in a dose- and time-dependent manner. Besides, GANT61 inhibited Notch1, Jagged1, Jagged2 and Hes1 expressions in a dose- and time-dependent manner as well. In rescue experiments, Notch1 upregulation attenuated the inhibition of cell proliferation, promotion of cell apoptosis, induction of G1/G0 cycle retardation and repression of Notch signaling pathway induced by GANT61 treatment in RPMI-8226 and U266 cells. : GANT61 suppresses cell proliferation, promotes cell apoptosis and induces G1/G0 cycle retardation with a dose- and time-dependent manner through inhibiting Notch pathway in MM. ABBREVIATIONS: MM: Multiple myeloma; Hh: Hedgehog; EMT: epithelial mesenchymal transition; AML: acute myeloid leukemia; GANT61: GLI antagonist; DMSO: dimethyl sulfoxide; CCK-8: Cell Counting Kit 8; C-Caspase 3: Cleaved Caspase 3; Bcl-2: B-cell lymphoma-2; RT-qPCR: real-time quantitative polymerase chain reaction; OD: optical density; PTCH1: Patched1.
目的:本研究旨在探讨 GANT61 对调节细胞增殖、细胞凋亡和细胞周期的影响,并探讨 GANT61 是否通过抑制 Notch 通路在多发性骨髓瘤(MM)中发挥作用。
方法:用 GANT61(0、2.5、5.0、10.0、20.0、30.0、40.0、50.0μmol/L)处理 RPMI-8226 和 U266 细胞 18、24 和 36 小时(h),用细胞计数试剂盒 8 检测细胞增殖。然后用 0、2.5、5.0、10.0μmol/L 的 GANT61 处理这些细胞 24 小时,或用 10.0μmol/L 的 GANT61 处理 0、18、24 和 36 小时,用 AV/PI、Western blot 和 PI 染色检测细胞凋亡率、凋亡标志物和细胞周期。用 qPCR 和 Western blot 检测 Notch1、Jagged1、Jagged2 和 Hes1 的表达。通过上调 Notch1 进行进一步的挽救实验。
结果:在 RPMI-8226 和 U266 细胞中,GANT61 呈剂量和时间依赖性抑制细胞增殖,增加细胞凋亡率和 G1/G0 期细胞百分比,同时降低 S 期细胞百分比。此外,GANT61 也呈剂量和时间依赖性抑制 Notch1、Jagged1、Jagged2 和 Hes1 的表达。在挽救实验中,Notch1 的上调减弱了 GANT61 处理对 RPMI-8226 和 U266 细胞增殖的抑制、对细胞凋亡的促进、对 G1/G0 周期阻滞的诱导以及对 Notch 信号通路的抑制作用。
结论:GANT61 通过抑制 Notch 通路,以剂量和时间依赖的方式抑制多发性骨髓瘤细胞增殖,促进细胞凋亡,诱导 G1/G0 周期阻滞。
J Cancer Res Clin Oncol. 2016-12
J Hematol Oncol. 2017-1-21
J Exp Clin Cancer Res. 2016-11-28
Front Oncol. 2025-7-29
Front Immunol. 2025-7-18
Oncol Rep. 2024-9
J Tradit Complement Med. 2024-1-5
BMC Mol Cell Biol. 2022-8-6
Cancers (Basel). 2021-9-26
J Hematol Oncol. 2017-1-21
Stem Cells Int. 2016
Oncotarget. 2015-6-10
Blood. 2015-4-2